文献库搜索 | GeneLibs

Lang(Y),Deng(M),Yang(J) Front Pharmacol None

...BRCA1/2 mutations. The addition of apatinib, an anti-angiogenic agent, enhances treatment outcomes. However, the economi...

Shern(TP),Chamberlain(V),Holt(LR),Gadd(MA)... Breast Cancer Res Treat 2026-08-12

...BRCA1/2 mutations (38.9% vs. 7.2%, p < 0.001), bilateral surgery (92.6% vs. 67.7%, p < 0.001), and sentinel lymph node b...

Lynce(F),Ru(M),Luo(L),Miranda(M),Xu(X),Isa... Breast Cancer Res Treat 2026-08-12

...BRCA1/BRCA2 mutation (BRCAm) is not well characterized. This retrospective, observational study explored the real-world ...

Sanguedolce(F),Mazzucchelli(R),Conteduca(V... Diagnostics (Basel) 2026-07-27

BRCA1/2 alterations have emerged as clinically relevant biomarkers in prostate cancer because of their prognostic signif...

Lai(E),Pierantoni(F),Zampiva(I),Bimbatti(D... Cancers (Basel) 2026-07-25

...BRCA1 (1.39%) being the most common alterations. A family history of breast, ovarian, or prostate cancer strongly predic...

Markowska(A),Wolski(H),de Mezer(M) Int J Mol Sci 2026-07-25

...BRCA1 carriers, but the evidence remains exploratory. In breast cancer, intratumoral bacteria may shape the immune micro...

Dos Santos(ES),Cicilini(AL),Simões(MFE),Ba... Int J Mol Sci 2026-07-28

Poly(ADP-ribose) polymerase inhibitors (PARPis) have demonstrated remarkable efficacy in tumors carrying BRCA1/2 pathoge...

Abinawanto,Sophian(A) Environ Mol Mutagen 2026-06-00

...BRCA1/2-mutant tumors. Despite initial efficacy, resistance inevitably emerges, limiting long-term clinical benefit. Thi...

Abdel-Razeq(H),Bani Hani(H),Alafeef(S),Tam... Front Oncol None

...BRCA1 P/LP variants were identified. Germline P/LP variants are common in young male patients with cancer, particularly ...

Gao(J),Wang(S),Huang(A),Wang(H),Xiao(Z) AME Case Rep None

...BRCA1 mutation. After completion of multidisciplinary neoadjuvant systemic therapy, the patient underwent E-NSM with imm...